Advancing Chimeric Antigen Receptor-Engineered T-Cell Immunotherapy Using Genome Editing Technologies: Challenges and Future Prospects


  • Arash Salmaninejad Student Research Committee, Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Atieh Eslahi Student Research Committee, Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Farzaneh Alizadeh Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Majid Mojarrad Medical Genetics Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Yousef Jafari Abarghan Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
چکیده مقاله:

Chimeric antigen receptor engineered-T (CAR-T) cells also named as living drugs, have been recently known as a breakthrough technology and were applied as an adoptive immunotherapy against different types of cancer. They also attracted widespread interest because of the success of B-cell malignancy therapy achieved by anti-CD19 CAR-T cells. Current genetic toolbox enabled the synthesis of CARs receptors which are targeted against tumor-specific antigens, and enabled to arbitrarily T-cells function reprogramming. Approximately all of CAR-T cell based studies apply autologous CAR-T cells in which, modified T-cells are engineered using patient’s own T cells. Currently, four different generation of CAR-T cells have been developed, and the evolution of this kind of therapy illustrates an excellent example of the application of basic research into the clinical trial stage. However, development of allogenic CAR-T cells can be a turning point for CAR-T cells therapy. Appearance of the reliable gene editing approach, CRISPR/Cas9 system, provided a new hope for designing universal CAR-T cells which are off-the-shelf, and enable to use for treatment of any patient with any kind of tumor.This review outlined four different generations of CAR-T cells. Also, we discussed different types of genome editing systems especially CRISPR/Cas9 system, and their capabilities for generating engineered T-cells. Additionally, we tried to explain challenges faced in improving universally generated T-cells.  

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer

CD4+ and CD8+ T lymphocytes are powerful components of adaptive immunity, which essentially contribute to the elimination of tumors. Due to their cytotoxic capacity, T cells emerged as attractive candidates for specific immunotherapy of cancer. A promising approach is the genetic modification of T cells with chimeric antigen receptors (CARs). First generation CARs consist of a binding moiety sp...

متن کامل

Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges

Recent years have witnessed much progress in both basic research and clinical trials regarding cancer immunotherapy with chimeric antigen receptor (CAR)-engineered T cells. The unique structure of CAR endows T cell tumor specific cytotoxicity and resistance to immunosuppressive microenvironment in cancers, which helps patients to better tackle the issue of immunological tolerance. Adoptive immu...

متن کامل

Chimeric antigen receptor T-cell immunotherapy tackles blood cancers.

intervention studies, assess change, and establish relationships with theoretically relevant factors and clinically important outcomes such as mortality. " The instrument has a broad content coverage, [has] very high reliability, and is strongly linked to self-confidence about engaging in health decisions, " Dumenci said. Completing CHLT-30 takes 10–15 minutes , and the score reflects the numbe...

متن کامل

A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy

Adoptive cell therapy using chimeric antigen receptor (CAR)-engineered T cells has emerged as a very promising approach to combating cancer. Despite its ability to eliminate tumors shown in some clinical trials, CAR-T cell therapy involves some significant safety challenges, such as cytokine release syndrome (CRS) and "on-target, off-tumor" toxicity, which is related to poor control of the dose...

متن کامل

Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects

Recent studies have highlighted the successes of chimeric antigen receptor-modified T- (CART-) cell-based therapy for B-cell malignancies, and early phase clinical trials have been launched in recent years. The few published clinical studies of CART cells in solid tumors have addressed safety and feasibility, but the clinical outcome data are limited. Although antitumor effects were confirmed i...

متن کامل

Chimeric Antigen Receptor (CAR) T-Cell Therapy.

Surgery, chemotherapy, and radiation therapy have been the foundation of cancer treatment. Advances in the field of immunology (a branch of science that studies all aspects of the immune system) have led to a greater understanding of the ways in which the body’s own defenses can be used for treatment of blood cancers. Cancer researchers are now studying how the immune system can help destroy ca...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ذخیره در منابع من قبلا به منابع من ذحیره شده

{@ msg_add @}

عنوان ژورنال

دوره 5  شماره 2

صفحات  0- 0

تاریخ انتشار 2019-08

با دنبال کردن یک ژورنال هنگامی که شماره جدید این ژورنال منتشر می شود به شما از طریق ایمیل اطلاع داده می شود.

کلمات کلیدی

میزبانی شده توسط پلتفرم ابری

copyright © 2015-2023